SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending due to its upcoming inclusion in the Nasdaq-100 index, which is fueling significant buying pressure and speculation as investors anticipate forced demand from index funds. The community remains deeply divided, with many debating whether the stock is undergoing an unprecedented AI-driven growth cycle or if it has reached a precarious valuation peak as it approaches the 1,000 mark.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community anticipates potential early FDA approval for its DMD therapy, Deramiocel, with many investors closely monitoring the upcoming CBER leadership appointment as a pivotal catalyst. Discussions are heavily focused on the stock's resilient price action, institutional accumulation, and the potential for a significant valuation re-rating following approval, despite ongoing volatility driven by sector-wide market factors.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently capturing attention as market participants analyze a potential re-rating driven by aggressive share buybacks, a massive undervaluation relative to its free cash flow, and persistent buyout rumors involving major tech players. While the stock has remained in a long-term consolidation range, the community is actively debating the upcoming strategic vision of the new CEO, with many investors anticipating that impending operational updates or potential consolidation will finally break the stock out of its current sideways pattern.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant volatility as investors debate the impact of aggressive AI infrastructure spending and mounting debt against the company's long-term cloud growth potential. The stock remains a heavily discussed battleground, with community sentiment split between those viewing the current price as a generational buying opportunity and others concerned about the sustainability of its AI-driven capital expenditure cycle.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors focus on its pivot toward AI infrastructure and optical networking, fueled by key partnerships with major industry players and recent government defense contract awards. The community is actively discussing the stock's potential for a multi-year growth trajectory, with many comparing its current positioning to other high-performing tech infrastructure firms.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is currently rallying behind a momentum-driven short squeeze, fueled by significant futures liquidations and anticipation surrounding its real-world event roadmap in 2026. While the community is actively debating the project's sustainability and potential for further gains, skeptics are expressing concerns over possible market manipulation and the long-term risks associated with the asset's rapid ascent.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is currently a focal point for investors debating whether its deep integration into enterprise creative workflows serves as a durable moat against AI-driven disruption or if the stock is a value trap. While the community is split, bullish sentiment is building around aggressive share buybacks and the company's strong cash flow, with many participants actively monitoring for potential leadership changes ahead of the upcoming annual meeting.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is seeing significant social media activity as traders speculate on a potential short squeeze, citing extremely limited share availability and high borrow fees. The community is actively drawing parallels between the current setup and past parabolic moves in other low-float tickers, with many looking for a breakout triggered by heavy volume.

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. It focuses on the development of new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The company was founded in February 2016, and is headquartered in San Diego, CA.

ImageneBio Inc.

ImageneBio, Inc.

ImageneBio is generating significant investor attention following a 30 million dollar private placement aimed at advancing their clinical pipeline for hair loss and skin disease treatments. While some traders are focused on the stock's potential for a breakout based on its current valuation relative to cash, others are debating the long-term clinical risks and the impact of the dilutive financing on the share price.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is driving significant market attention as its daraxonrasib trial for pancreatic cancer shows strong survival benefits, positioning the company as a potential leader in the targeted oncology space. The community is actively debating its high valuation and M&A potential, with many investors focusing on the company's robust cash position and the massive unmet need for new treatments in the pancreatic cancer market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tudor Investment Corp ET AL Invests $1.43 Million in Supernus Pharmaceuticals, Inc. $SUPN

Tudor Investment Corp ET AL bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with...

Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Supernus Pharmaceuticals stock on March 3rd. T...

Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Cross Above 200-Day Moving Average - Should You Sell?

Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Cross Above 200-Day Moving Average - Should You Sell...

Aberdeen Group plc Acquires New Shares in Supernus Pharmaceuticals, Inc. $SUPN

Aberdeen Group plc acquired a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the...

Hennion & Walsh Asset Management Inc. Has $4.01 Million Position in Supernus Pharmaceuticals, Inc. $SUPN

Hennion & Walsh Asset Management Inc. lessened its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 20.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 80,651 shares of the specialty pharmaceutical company's stock aft...

Supernus Pharmaceuticals, Inc. $SUPN Stock Holdings Lowered by JPMorgan Chase & Co.

JPMorgan Chase & Co. trimmed its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 45.6% in the third quarter, according to its most recent Form 13F filing with the...

Tudor Investment Corp ET AL Makes New Investment in Supernus Pharmaceuticals, Inc. $SUPN

Tudor Investment Corp ET AL bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the third quarter, according to its most recent filing with the Securities...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) have been assigned a consensus recommendation of "Hold" from the seven ratings firms that are covering the firm, MarketBeat...

Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Pass Above 200-Day Moving Average   - What's Next?

Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Crosses Above 200-Day Moving Average - Should You Sell...

Supernus Pharmaceuticals (NASDAQ:SUPN) VP Sells $2,514,000.00 in Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) VP Padmanabh Bhatt sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $50.28, for a total transaction of $2,514,000.00. Following the...

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.

Supernus Pharmaceuticals Inc

Start of a real move higher

Dead cat - we retest the lows

Show me the results

Software is bouncing hard today. Is this the start of a sustained recovery or just a dead cat bounce before we retest the lows?

Current Price	$49.72
Prev Close	$50.68
Open	$50.45
Dividend Yield	0.00%
50-Day Moving Average	$51.26
Beta	0.56
Avg. Volume	630,176.51
PE Ratio	-74.10

52-Week High	$59.68
52-Week Low	$29.16
Market Capitalization	$2.92B
EPS (Annual)	-$0.6829
Price to Book	2.74
Revenue Per Employee	$924,102.83

SUPN
Supernus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SUPN News

SUPNSupernus Pharmaceuticals Inc